Johnson & Johnson $JNJ Shares Purchased by Cooper Financial Group

Cooper Financial Group boosted its position in Johnson & Johnson (NYSE:JNJ) by 29.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,098 shares of the company’s stock after buying an additional 3,247 shares during the period. Cooper Financial Group’s holdings in Johnson & Johnson were worth $3,732,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of JNJ. Outlook Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at about $28,000. Matrix Trust Co raised its holdings in Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares in the last quarter. Montgomery Financial Services LLC purchased a new position in Johnson & Johnson during the second quarter worth about $43,000. Hyposwiss Advisors SA acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $42,000. Finally, Polaris Financial Partners purchased a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $56,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 87,569 shares of company stock worth $23,064,544. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent analyst reports. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Royal Bank Of Canada lifted their price target on Johnson & Johnson from $287.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday. TD Cowen upped their price objective on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. The Goldman Sachs Group reiterated a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. Finally, Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $276.22.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst support: Guggenheim reaffirmed its “Buy” rating and set a $287 price target, implying further upside from recent trading levels. RBC Capital Markets has also maintained its “Buy” rating. RBC Capital Keeps Their Buy Rating on Johnson & Johnson
• Positive Sentiment: Pipeline progress: Johnson & Johnson reported that the Tecvayli-Talvey combination reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in relapsed or refractory multiple myeloma. The results support potential expansion of the company’s oncology franchise. 2026 Cancer Treatment Advances
• Positive Sentiment: Two-year Phase 3 data for oral psoriasis treatment ICOTYDE showed sustained skin clearance and consistent safety through Week 112, potentially adding another growth product to the Innovative Medicines portfolio. ICOTYDE Long-Term Psoriasis Data
• Positive Sentiment: Recent quarterly results showed 6.6% revenue growth, adjusted EPS above consensus and increased 2026 guidance, reinforcing the view that J&J may be developing into more than a purely defensive healthcare stock. Johnson & Johnson Is Becoming a Growth Stock
• Neutral Sentiment: J&J’s 64-year record of dividend increases continues to attract income investors, although the stock’s valuation means investors are paying for part of that quality and expected growth.
• Negative Sentiment: Investors remain concerned about upcoming patent and biosimilar pressure, a slower MedTech recovery, and ongoing talc litigation. These issues could limit earnings growth and offset strength in Innovative Medicines. Johnson & Johnson Dividend and Risk Analysis

Johnson & Johnson Price Performance

Shares of JNJ stock traded up $3.47 during midday trading on Wednesday, reaching $258.25. 5,394,094 shares of the company traded hands, compared to its average volume of 7,981,786. The firm’s 50 day simple moving average is $265.71 and its two-hundred day simple moving average is $248.78. The firm has a market cap of $622.35 billion, a PE ratio of 29.92, a price-to-earnings-growth ratio of 2.48 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the prior year, the firm posted $2.77 EPS. The company’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts expect that Johnson & Johnson will post 11.54 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 62.11%.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.